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ABSTRACT 
Idiopathic nondementing Parkinson’s disease (PD) is marked by progressive loss of dopaminergic neurons in the sub-
stantia nigra pars compacta and ventral tegmental area. Recent brain imaging work implicates these structures in do-
pamine modulated networks subserving episodic memory. These findings are of relevance to PD because they suggest 
that dopamine depletion contributes to the disease-dependent decline in episodic memory, and therefore, this decline 
should, at least partially, be remediated by dopaminergic medication. Recognition memory (RM), recollection and fa-
miliarity during recognition was examined in 17 PD patients, 12 of whom were medicated with a D2 dopamine agonist 
(pramipexole or ropinirole) and l-dopa, with a further 5 PD control patients on l-dopa but no D2 agonist. Memory was 
tested “ON” and, following a period of medication withdrawal, “OFF” and compared to a group of 14 matched healthy 
volunteers (HV). The HVs were also tested twice in the absence of medication. The patients on the agonists PD showed 
significant impairments in recollection ON- and OFF-medication, whereas the l-dopa control patients exhibited a de-
cline in OFF-recollection only. RM and familiarity were spared in both groups ON- and OFF-medication. These find-
ings suggest that D2 dopamine agonists (combined with l-dopa) contribute to disease-dependent episodic memory im-
pairment.  
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1. Introduction 
We report an investigation of l-dopa and second genera-
tion nonergoline dopamine agonists (“D2 agonists”) on 
the recollection of episodic details and the assessment of 
familiarity during recognition in patients with nonde-
menting idiopathic Parkinson’s disease (PD). This study 
builds on previous a previous report [1] of a selective 
impairment in recollection in moderate PD when opti-
mally medicated with dopaminergic medication. Fur-
thermore, the data indicated that the severity of the rec-
ollection deficit decreased when the same patients were 
tested in following a 12 - 14 hour over-night period of 
medication withdrawal. In contrast, familiarity showed 
relative sparing in both unmedicated and medicated con-
ditions.   
A dissociation between recollection and familiarity in 
medicated PD has been reported previously, although 
consensus is lacking regarding the direction of this dis-
sociation. There are a number of reports [2-5] of a selec-
tive deficit in recollection; whereas others [6,7] have 
found a more pronounced impairment in familiarity. Re-
cent evidence of a double dissociation between recollec-
tion and familiarity in the same study [8], albeit in dif-
ferent patient groups, implies that methodological dif-
ferences between studies may contribute to the direction 
of the dissociation.  
The suggestion that recollection and familiarity doubly 
dissociate in Parkinson’s is consistent with the dual 
process view of recognition memory [9] and Aggleton 
and Brown’s [10,11] still controversial neuroanatomical 
model of recognition memory. In this model, recollection 
is reliant on an extended hippocampal circuit whereas 
familiarity is dependent on a separate network, extending 
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from the perirhinal cortex in the medial temporal lobe to 
the mediodorsal thalamus and frontal lobes.   
The medial temporal lobe structures identified in Ag-
gleton and Brown’s model, and particularly the hippo-
campus, are dependent on dopaminergic modulation, and 
are therefore, also vulnerable to dopamine depletion, the 
hallmark pathology of PD.  
Rodent studies show dopamine induces long-term po-
tentiation (a form of synaptic plasticity believed to un-
derlie memory storage) in both the CA1-3 fields of the 
hippocampus [12-15] and the perirhinal cortex [16-18], 
with D2 dopamine receptors critically involved in this 
process [19-21].  
Brain imaging evidence indicates dopamine modulates 
activity in the substantia nigra pars compacta, and 
mesolimbic circuit (involving the ventral tegmental area 
and the hippocampus) during the acquisition of novel 
associative information [22-29] and signals about past 
and future rewards and punishments [30-32].  
Episodic memory can also be manipulated by drugs 
which either block or promote dopamine activity. So, for 
example, injecting the dopamine D1 and D2 antagonist 
D-AP-5 into rodent hippocampus impairs maze learning 
[32-34]; whereas administration of D1 agonists, such as 
piribedil and bromocriptine, and SKF 38393 and SKF 
81297, promotes spatial memory in young adult rats 
[35,36] and aged rats [37]. In humans, l-dopa (100 mg 
plus 25 mg carbidopa) has also been shown to increase 
verbal encoding in healthy young and older adults adults, 
as well as stroke patients [38-40]. 
The suggestion that routine dopaminergic medication 
used to control motor symptoms in PD has the capacity 
to affect cognitive function is well established. PD pa-
tients medicated with l-dopa show improved working 
memory [41-43], dual-tasking [44,45], task-switching 
[46-48], feedback-based sequence learning [49], and 
verbal fluency [50] compared to their unmedicated per-
formance. However, l-dopa can also impair self-ordered 
pointing and conditional associative learning [50], prob-
abilistic reversal learning [46], extinction learning [51], 
betting strategies in a gambling task [47] and the Wis-
consin Card Sorting Test [52].   
It’s been proposed that the direction in which l-dopa 
affects a particular cognition is dependent on the integ-
rity of the underlying dopamine-modulated neural cir-
cuitry. According to the l-dopa overdose hypothesis, the 
requisite dopaminergic state necessary to control motor 
symptoms has the potential to move the same patient 
towards and away from their optimum for certain cogni-
tive functions [46,50,53,54]. The relationship between 
the efficiency of neuronal activity and the state of dopa-
minergic modulation is represented by an inverted 
U-shaped curve with cognitive functions declining with 
deviation away from optimum dopamine levels, indicated 
by the centre of the curve. Accordingly, where de novo 
patients show impairments in working memory for ex-
ample but medicated patients do not [55], l-dopa serves 
to restore depleted dopamine levels in the neural struc-
tures subserving working memory. By contrast, when 
l-dopa is withdrawn and formally deficient cognitions, 
such as probabilistic reversal learning, are remediated, 
then the effect of l-dopa is to “overdose” neural circuits 
where dopamine modulation remains relatively spared.   
D2 agonists are frequently combined with l-dopa in 
PD. Their effects have been less extensively studied 
compared to l-dopa, although they have been linked to a 
“dopamine dysregulation syndrome”, where some pa-
tients engage in risk-taking behaviour such as pathologi-
cal gambling and hypersexuality [56,57]. There is also 
some evidence that D2 agonists may supportworking 
memory and task switching, but impairs probabilistic 
reversal learning [46,58].  
In sum, the findings from animal research, pharma-
cological and brain imaging studies of healthy volunteers 
support a role for dopamine modulation of hippocampal, 
and to a lesser extent perirhinal, memory processes. 
Based on the underlying level of dopamine activity in 
these memory structures, as well as prefrontal areas 
which support strategic memory, the l-dopa overdose 
hypothesis predicts differential effects on memory. Stud-
ies of dopaminergic medication and executive function in 
PD indicate that both l-dopa and D2 agonists have the 
potential to both remediate and impair executive function. 
Although only one study to date has examined the effect 
of dopaminergic medication on episodic memory, there 
is good reason, based on the evidence reviewed, to sus-
pect that the recollection of episodic details may also be 
affected by dopaminergic medication.  
The aim of our investigation was to investigate the ef-
fect of D2 agonists on the recollection of episodic details 
and the assessment of familiarity during recognition. 
Because D2 agonists are frequently combined with 
l-dopa, a separate control group of patients on l-dopa but 
not agonists will also be assessed.  
The procedure adopted in this study is the controlled 
medication withdrawal procedure, with memory assessed 
in the same patients when unmedicated or in an OFF and 
again after patients have taken their routine medication 
(termed medicated or ON state). This procedure is less 
prone to the confounds of differences in disease severity 
compared to the alternative procedure of comparing de 
novo, i.e. never medicated, patients with the same indi-
viduals at a later stage after dopaminergic medication 
administration, or a different already-treated group.  
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The first set of predictions applies to the OFF-state, 
where we expect patients in both the D2 agonist group 
and the l-dopa group (patients on l-dopa monotherapy or 
in combination with an enzyme inhibitor) to exhibit a 
dissociation between deficient recollection and preserved 
familiarity.   
The second set of predictions applies to the ON- 
medication state. The l-dopa group is expected to show 
enhanced recollection. According to the l-dopa overdose 
hypothesis, patients in the l-dopa group should show an 
enhancement of recollection. Because the mode of action 
of D2 agonists on cognition is less well formulated, the 
following predictions are driven by empirical observa-
tions rather than theory. Inspection of medication regi-
men of patients reported in our previous study [1], indi-
cated that l-dopa plus a D2 agonist failed to remediate 
recollection and if anything, served to increase the mag-
nitude of the OFF-medication recollection impairment 
further. We also expect familiarity to be spared in line 
with previous empirical results [1,2,4] and the proposal 
that this type of memory is reliant on a different non-
dopamine-dependent neural pathway to that which sup-
ports recollection.  
Finally, within-group comparisons of recollection 
memory should reveal significant differences ON and 
OFF medication, with patients in the D2 agonist group 
displaying significantly improved OFF-compared to ON- 
recollection rates. By contrast, the direction of this effect 
should be reverse in the l-dopa group, with improved 
recollection ON compared to OFF-medication.  
2. Participants and Methods 
2.1. Participants 
A group of seventeen patients in the mild to moderate 
stages of Parkinson’s (mean medicated Hoehn and Yahr 
[59] [HY] disease severity rating 2.6, range: 1 - 4) were 
recruited from the Parkinson’s disease outpatient clinic in 
the Department of Neurology, University Hospital of 
North Staffordshire. During a clinical interview with a 
consultant neurologist (SJE), patients were screened for 
adverse clinical events or issues that might affect per-
formance (e.g. deep brain stimulation, dyskinesias, do-
pamine dysregulation syndrome, drastic medication 
changes, fatigue, distress, commenced dopaminergic 
medication 2 months prior to commencement of the 
study).   
Twelve patients of this initial cohort were taking a D2 
agonist, either pramipexole or ropinirole, combined with 
l-dopa. The remaining five patients were taking l-dopa 
with/without an enzyme inhibitor only. Both patient sub-
groups were matched for age (t = –1.57, p = 0.14), pre-
morbid IQ (National Adult Reading Test [60], [NART]: t 
= –0.20, p = 0.84), current levels of functioning (Mini- 
Mental State Examination [61], [MMSE]: t = –0.09, p = 
0.93; The Cambridge Examination for Mental Disorders 
of the Elderly [62], [CAMCOG]: t = 1.23, p = 0.24), de-
pression rating (Hamilton Depression Inventory [63], 
[HDI]: t = 0.25, p = 0.81); motor symptom severity OFF- 
and ON-medication (Unified Parkinson’s Disease Rating 
Scale [64], [UPDRS]: t = 0.73, p = 0.48 and t = 0.17, p = 
0.87, respectively), l-dopa equivalent dose (t = –1.73, p = 
1.00), disease duration (t = –0.11, p = 0.91) and HY 
score (t = 0.27, p = 0.79). The raw data are presented in 
Table 1.  
A single group of 14 healthy volunteers (HV) served 
as controls for the D2 agonist and l-dopa patient sub-
groups. The HV matched both patient subgroups for age 
(D2 agonist: t = 0.02, p = 0.98; l-dopa: t = –1.43, p = 1.0), 
premorbid IQ (D2 agonist: t = –0.32, p = 0.75; l-dopa: t = 
–0.25, p = 0.8), current levels of functioning on the 
MMSE and CAMCOG (D2 agonist: t = –0.93, p = 0.36 
and t = 1.16, p = 0.25, respectively; l-dopa: t = –0.65, p = 
0.52 and t = 2.0, p = 0.054, respectively) but not depres-
sion (D2 agonist: t = –2.23, p = 0.03; l-dopa: t = –2.91, p 
= 0.01). The raw data for the HV groups are also pre-
sented in Table 1. 
Exclusion criteria for all participants included a MMSE 
score of 25 or less, presence of neurological or psychiat-
ric history (apart from PD in the index groups), history of 
substance abuse (including alcoholism), antidepressants, 
learning difficulty (including dyslexia), or English as a 
second language.  
2.2. Procedure 
Two versions of a “yes/no” recognition memory test 
(“RMT1” and “RMT2”) were constructed from a pool of 
three hundred and twenty 4-6 letter words, and matched 
for word frequency (RMT1: mean = 115.4 per million, 
range 1 - 1461, SD = 160.51; RMT2: mean = 115.65 per 
million, range 1 - 1789, SD = 160.87) concreteness 
(RMT1: mean = 467.9, SD = 6.36; RMT2: mean = 466.9, 
SD = 8.79) and imageability (RMT1: mean = 487.2, SD 
= 6.08; RMT2: mean = 486.5, SD = 5.66), using published 
norms [65,66], and for relative contribution of familiarity 
and recollection at test.   
At study, participants saw a mixture of 80 high and 
low frequency words for 3-seconds each (3-second inter- 
stimulus interval) and made a judgement as to whether 
the word was pleasant, unpleasant or neutral. Immedi-
ately after completing the study phase, recognition using 
the yes/no procedure was tested by presenting each of the 
studied words (targets) randomly intermixed with 80 
high and low frequency new words or lures, that were      
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Table 1. Participant demographic, neuropsychological and clinical (patients only) features. 
UPDRS Medication 
 HDI Age MMSE NART CAMCOG HY IllnessDuration OFF ON l-dopa D2 agonista,b Inhibitorc,d
Healthy Volunteers (HV)          
HV 1 3 59 29 119 102        
HV 2 2.7 60 30 121 102        
HV 3 2.2 66 30 119 102        
HV 4 3 64 29 109 101        
HV 5 0.7 72 30 121 99        
HV 6 4 79 29 118 103        
HV 7 11 64 30 124 102        
HV 8 4.2 67 30 118 102        
HV 9 7 71 30 119 103        
HV 10 3 77 30 124 104        
HV 11 2 60 30 122 104        
HV 12 1 68 30 110 98        
HV 13 4.4 54 29 107 99        
HV 14 7 69 28 102 100        
MEAN 4 66 29.57 116.6 101.5        
SD 2.8 7 0.646 6.823 1.870829        
D2 agonist subgroup (DA)          
DA 1 3 64 29 109 99 3 6 17 15 250 16a 1c 
DA 2 4 71 30 127 98 2 6 10 10 200 7a 1c 
DA 3 28 61 30 115 102 3 8.5 22 14 400 1b 0 
DA 4 9.8 77 29 117 98 3 7 15 16 500 16b 0 
DA 5 18 64 30 98 101 4 10 23 20 375 16 b 0 
DA 6 14 65 28 113 103 2 5 8 6 300 24b 200d 
DA 7 1 75 30 124 104 2.5 3 13 5 250 16b 0 
DA 8 3.8 62 29 126 103 2.5 4 7 4 250 9b 0 
DA 9 4 59 30 126 100 2.5 2 11 11 100 11b 0 
DA 10 11 69 30 123 100 3 14 17 14 525 11b 0 
DA 11 6 68 30 114 100 2 3 9 6 100 12b 0 
DA 12 4 55 30 118 100 3 5 7 7 450 12b 0 
MEAN 8.9 66 29.58 117.5 100.6667 2.71 5.63 13.3 10.7 308.3 12.8 0 
SD 7.8 7 0.63 7.93 2.06 0.58 3.24 5.58 5.14 143.2 5.94 0 
L-dopa subgroup           
L-dopa 1 7.5 65 30 125 98 1 3 9 8 300   
L-dopa 2 8.5 63 29 109 99 2 4 6 6 250   
L-dopa 3 6.5 73 30 124 102 2.5 6 1 1 400   
L-dopa 4 8.4 79 29 107 98 3 8 17 16 412.5   
L-dopa 5 7 76 30 123 100 4 12 17 17 1000   
MEAN 7.6 71 29.6 117.6 99.4 2.5 6.6 10 9.6 472.5   
SD 0.9 6.9 0.55 8.82 1.67 1.12 3.58 7 6.8 302.6   
Notes: Significantly different from 1healthy control group at *p < 0.05; Abbreviations: SD = 1 standard deviation; MMSE = Mini-Mental state examination; 
NART = National Adult Reading Test; HDI = Hamilton Depression Inventory; CAMCOG = The Cambridge Examination for Mental Disorders of the Eld-
erly-Revised; HY = Hoehn and Yahr; UPDRS = Unified Parkinson’s Disease Rating Scale; ON = medicated state; OFF = unmedicated state; dopamine D2 
gonists: apramipexole, bropinirole. Enzyme inhibitor: cMOAI, dCOMT.  a 
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matched to the targets for mean word frequency, con-
creteness and imageability. Each word was presented 
individually, and recognition judgements were made 
within a 3-second response window.  
Correct identification of a target item was defined as a 
hit, whilst false recognition of a lure was termed a false 
alarm. Following each endorsement, irrespective of 
whether it was a hit or false alarm, participants made a 
subjective judgement of their recognition experience in 
terms of either feelings of familiarity without any recol-
lection (“know” response) or a specific recollection of the 
item having been previously presented (“remember” re-
sponse). The second stage was not time constrained. Par-
ticipants were given practice trials prior to completing 
both RMT1 and RMT2, and regular checks were made 
throughout the test phase to ensure that participants 
maintained a full understanding of the criteria for making 
a remember/know decision.   
To examine the effect of medication, patients were 
tested ON and OFF medication.   
In the ON-condition, patients were tested in the morn-
ing, 2 hours after taking their first medication of the day. 
To produce the OFF-state, patients were assessed at the 
same time of day having delayed their first morning 
medication. The time since last medication was 12 - 14 
hours. The HVs were also tested for 2 sessions, labelled 
“Blue” and “Green”. This label emphasized that there 
was no difference in “treatment” between the two sessions: 
the “Blue” was yoked to the OFF session of the patients, 
the “Green” to the ON session. The order of RMT1 and 
RMT2 were counterbalanced across the ON/Green and 
OFF/Blue sessions, and the order of ON/Green and 
OFF/Blue sessions were counterbalanced across partici-
pants.  
The study was approved by South Staffordshire NHS 
Research Ethics Committee. 
2.3. Performance Measures 
A correction has been made to the raw data to eliminate 
extreme scores [67]. It is assumed that recollection and 
familiarity are stochastically independent at retrieval, and 
therefore the independence formula has been applied to 
the corrected know data (Familiarity = know/[1-remem- 
ber]) [68]. Estimates of recognition memory and famili-
arity were then calculated using d’, and recollection is 
reported as a threshold measure (hits rate minus false 
alarms).   
2.4. Analyses 
The estimates of RM, familiarity and recollection were 
analyzed using a series of 2 by 3 Analysis of Variance 
(ANOVA) with Group as the betweens subject factor 
(HV versus the D2 agonist PD subgroup versus l-dopa 
control PD subgroup) and Condition the within subjects 
factor (OFF-medication/Blue versus ON-medication/ 
Green).   
The distributions of depression scores of the HV and 
PD subgroups were markedly different and the variances 
of the groups were heterogeneous. However Analysis of 
Covariance with depression as a covariate weren’t run 
because the mean depression score which would have 
been applied is above the score of any of the members of 
the comparison group.  
3. Results 
Raw hit and false alarm rates for recognition memory 
(RM), know and remember judgements in the OFF- 
medication/Blue and ON-medication/Green conditions 
by group are presented in Table 2. 
Estimates of RM, familiarity and recollection in the 
OFF-medication/Blue and ON-medication/Green condi-
tions by group are presented in Table 3 and Figure 1.   
The first 2 by 3 ANOVA of RM (d’) showed no main 
effects of either Group (HV versus PD, medication sub-
groups collapsed, F[1,34] = 2.14, p = 0.15) or Condition 
(OFF-medication/Blue and ON-medication/Green, F[1,34] 
= 0.15, p = 0.7), and the Interaction between Group and 
Condition was also not significant (F[1,34] = 0.01, p = 
0.81). The second 2 by 3 ANOVA of familiarity (d’) 
revealed the same pattern of results with no main effects 
of either Group (HV versus PD, medication subgroups 
collapsed, F[1,34] = 0.82, p = 0.37) or Condition (F[1,34] 
= 0.3, p = 0.59), and the Interaction was again not sig-
nificant (F[1,34] = 0.6, p = 0.81). Taken together, these 
results do not give any indication that neither disease nor 
medication effect RM or familiarity in this cohort of PD 
patients.  
The next 2 by 3 ANOVA which analysed recollection 
estimates revealed a main effect of Group (HV versus 
PD, medication subgroups collapsed, F[1,34] = 6.99, p = 
0.012), but neither Condition (OFF-medication/Blue and 
ON-medication/Green, F F[1,34] = 0.28, p = 0.6) nor the 
Interaction (F[1,34] = 0.17, p = 0.69) were significant. 
Separate one-way ANOVA of OFF/Blue and ON/Green 
recollection rates with Group as the between-subjects 
variable showed a significant difference in OFF/Blue 
recollection (F[2,35] = 3.86, p = 0.03) and ON/Green 
recollection approached significance (F[2,35] = 2.77, p = 
0.08). A series of planned pair-wise comparisons re-
vealed OFF-medication recollection to be significantly 
lower in the agonist patients (p = 0.035) and the l-dopa (p 
= 0.027) compared to the HVs, there was no difference 
between the PD subgroups (p > 0.05). These findings in-
icate a general disease-dependent decline in recollection  d  
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Table 2. Mean hit and false alarm rates for recognition memory, know and remember rates in ON/Green and OFF/Blue con-
ditions by group. 
Recognition memory Know Remember 
OFF/Blue ON/Green OFF/Blue ON/Green OFF/Blue ON/Green GROUP 
HR FAR HR FAR HR FAR HR FAR HR FAR HR FAR 
Healthy volunteer group (n = 14) 
Mean 70.5 6.6 70.5 6.43 13.1 5.1 13.7 4.7 57.2 1.4 56.9 1.9 
SD 6.2 5.3 5.6 6.5 6.0 4.5 4.6 4.8 8.3 1.3 8.5 2.0 
D2 agonist subgroup (n = 12)  
Mean 59.4 5.1 60.3 6.1 15.3 3.9 19.0 4.8 45.3 1.3 42.4 1.6 
SD 12.2 4.2 13.4 4.6 5.7 4.3 9.1 3.3 16.4 1.7 18.2 2.3 
l-dopa subgroup (n = 5)  
Mean 58.80 6.20 64.20 8.8 19.20 4.40 20.60 5.80 38.60 1.80 43.60 2.80 
SD 12.28 7.56 8.59 10.45 4.09 4.22 15.37 8.26 16.14 3.49 17.36 5.22 
Notes and Abbreviations: HR = hit rate; FAR = false alarm rate; SD = 1 standard deviation; OFF = unmedicated state; ON = medicated state.  
 
Table 3. Estimates of ON-medication/Green and OFF-medication/Blue recognition, familiarity and recollection by partici-
pant group. 
RM (d’) Familiarity (d’) Recollection (HR-FAR) 
 
OFF/Blue ON/Green OFF/Blue ON/Green OFF/Blue ON/Green 
Healthy volunteer group (n = 14) 
MEAN 2.22 2.28 1.61 1.70 0.66 0.65 
SD 0.76 0.96 0.71 0.80 0.15 0.15 
D2 agonist subgroup (n = 12) 
MEAN 2.24 2.22 1.63 1.72 0.52* 0.50* 
SD 0.70 0.78 0.53 0.57 0.20 0.22 
L-dopa subgroup (n = 5) 
MEAN 2.26 2.47 1.68 1.86 0.45* 0.50 
SD 0.78 0.87 0.73 0.42 0.19 0.21 
Notes: significance level: *p < 0.05; Abbreviations: SD = 1 standard deviation; ON = medicated state; OFF = unmedicated state. 
 
independent of medication subgroup. ON-recollection 
was also significantly lower in the agonist patients com-
pared to the HVs (p = 0.036), but not in the l-dopa con-
trol group (p > 0.05). There was no difference between 
the PD subgroups (p > 0.05).  
4. Discussion  
In this study, the recollection of episodic details and the 
assessment of familiarity during recognition was exam-
ined in idiopathic, nondementing, moderate PD patients 
ON and OFF their routine dopaminergic medication. 
Patients were subdivided into two groups according to 
medication regimen: the index PD subgroup on a dopa-
mine D2 agonist (pramipexole or ropinirole) plus l-dopa 
(with/without an enzyme inhibito) and a second PD con-
trol subgroup on l-dopa (with/without an enzyme inhibi-
tor but no D2 dopamine agonists). Patient performance 
was compared to a set of demographically and neuro-
psychologically matched healthy control group.  
The key findings can be summarised as follows: Col-
lapsing the PD subgroups (dopamine agonist subgroup 
and l-dopa control subgroup) into a single group, and 
combining performance from both medication conditions 
(ON/Green and OFF/Blue-medication), revealed a selec-
tive deficit in recollection with sparing of overall recog-
nition memory and familiarity compared to the healthy 
controls. When the PD patients were separated into sub-
groups according to medication regimen, patients in both     
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Figure 1. Estimates of ON-medication/Green and OFF-medication/Blue recognition memory (upper), familiarity (middle) and 
recollection (lower) by participant group. Notes: Error bars represent standard errors of the mean; Abbreviations: OFF = 
nmedicated state; ON = medicated state. Significant at *p < 0.05.  u 
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the dopamine agonist (plus l-dopa) subgroup and l-dopa 
(only) control group exhibited significant impairments in 
recollection. However, when examined in an optimally 
medicated state the memory profile deviated, with recol-
lection deficits present in only the agonist subgroup. 
Taken together these findings suggest that the reported 
PD patients, irrespective of their medication regimen, 
show impairments in recollection—evident in the un-
medicated condition. The severity of this impairment 
increases when patients are medicated with dopamine 
agonist (plus l-dopa) but not l-dopa alone. It is unlikely 
that the differences in the ON-medication profile be-
tween the two PD subgroups can be explained by het-
erogeneity in PD phenotype [69,70], as both patient sub-
groups were matched for demographic, clinical and IQ- 
characteristics.  
The impact of dopaminergic medication on memory 
has largely been overlooked in recent years, and this is 
certainly the case in relation to studies of recollection and 
familiarity. To date, with the exception of one study [1], 
recognition memory processes have examined PD pa-
tients in a medicated state. This is an important consid-
eration, given the large body of evidence showing that 
l-dopa, and to a lesser extent pramipexole, can enhance 
and impair a range of executive functions including 
working memory and various forms of probabilistic re-
versal learning. There is good reason to suspect that 
dopaminergic medication may also affect episodic mem-
ory in PD, given the critical role of dopamine in modu-
lating medical temporal lobe memory structures, as well 
as prefrontal areas which may support strategic memory 
processes as well.  
This study replicates the array of previous studies by 
reporting a dissociation between relatively spared famili-
arity and deficient recollection [1,2,4]; the presence of 
medication-dependent effects on recollection but not 
familiarity [1]; and, for the first time, that the presence of 
a disease dependent decline in recollection is increased 
by dopamine D2 agonists but not l-dopa.  
It could be argued that the negative impact of D2 ago-
nists on recollection is secondary to the sometime re-
ported side-effects of somnolence and reduced vigilance 
of pramipexole and ropinirole [71,72]. However, this 
parsimonious explanation fails to stand up to scrutiny, 
since previous work has shown that D2 agonists, and 
pramipexole in particular, enhances rather than impairs 
working memory [53,58,73], and probabilistic reversal 
learning [53]. Since both working memory and probabil-
istic reversal learning are cognitively-demanding activi-
ties, if pramipexole-induced somnolence were to be a 
significant factor—since a decline in vigilance would 
certainly be evident on these tasks.    
A related point is the relationship between working 
memory and recollection. Previous studies have sug-
gested that an impairment in working memory underpins 
the decline in episodic memory in PD [74,75]. It should 
follow, therefore, that drugs which enhance working 
memory [53,58,71] should also exert (secondary) bene-
fits on recollection. Accordingly, if pramipexole im-
proves working memory in PD, and recollection deficits 
in PD are contingent, at least in part, on working memory 
deficits, then our D2 agonist group should show im-
proved recollection ON compared to OFF medication— 
which is in fact the opposite to that observed. The impli-
cation of these findings are that recollection deficits in 
PD patients medicated with D2 agonists are not just sec-
ondary to a decline in vigilance or working memory, but 
rather reflect primary memory deficits underpinned by 
abnormalities at D2 receptor sites in the medial temporal 
lobe.  
In support of this proposal, there is a large body of 
evidence documenting the presence of D2 receptors in 
the hippocampus [75-78] and their involvement in mem-
ory from studies examining post-mortem tissue [27], 
brain imaging [76] and injecting quinpirole, a D2 recep-
tor antagonist, into the hippocampus of rats [33].  
The smaller group of patients on l-dopa (montherapy 
or with an adjuvant enzyme inhibitors) showed a differ-
ent profile across the medication conditions. Rather than 
falling in line with the D2 agonists, l-dopa appeared to 
enhance recollection rather than deplete it further. This 
conclusion is based on the observation that in the OFF 
state, l-dopa patients’ recollection rate was impaired 
whereas in the ON state, this deficit was remediated and 
recollection rates in l-dopa and healthy control groups 
were comparable. This finding supports the predictions 
arising from the l-dopa overdose hypothesis: that cogni-
tive deficits contingent on dopamine depletion are reme-
diated by l-dopa. Whilst this effect has been reported 
previously for certain executive functions, this is the first 
study to report a beneficial effect of l-dopa on recollec-
tion memory in PD.   
The trend for patients in the l-dopa group to show 
remediation of their OFF-medication recollection scores 
when tested in an optimally medicated state (within 3 
hours of taking their first l-dopa morning dose) is con-
sistent with other recent studies reporting l-dopa en-
hances the acquisition and consolidation of an artificial 
vocabulary in a dose dependent relationship in young 
healthy males [39], verbal memory in PD [79] and object 
recognition memory in PD [80]. This effect appears to be 
limited to declarative memory, with the recent report by 
Shohamy, Myers, Geghman, Sage and Gluck [49] show-
ing l-dopa disrupts incidental learning, but showed spared 
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ability to generalise based on learned information. Cools 
et al. [47] noted that l-dopa medication remediates cog-
nitive inflexibility but increases impulsivity in Parkin-
son’s. Impulsivity in the current context could be inter-
preted as showing an increased tendency towards making 
false alarms. However, inspection of false alarm rates 
across the three groups in the medicated condition, as 
well as medicated and unmedicated false alarm rates 
within the l-dopa group specifically were unaffected by 
medication type or state.  
In conclusion, the results of the current study demon-
strate that nondementing moderate Parkinson’s can se-
lectively impair the recollection of episodic details dur-
ing recognition, and provides preliminary evidence that 
the severity of the recollection deficit is increased by D2 
dopamine agonists. 
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